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In turn, TGF-b suppresses the proinflammatory activation ofTransforming growth factor-b is involved in the pathogenesis
macrophages, suggesting a dual role for TGF-b in the inflam-of dialysis-related amyloidosis.
matory process of DRA. These observations may provide aBackground. Advanced glycation end product-modified
pathophysiologic link between TGF-b and DRA.b2-microglobulin (AGE-b2m) is an important component of
dialysis-related amyloidosis (DRA). Its presence induces mono-
cyte chemotaxis and the release of the proinflammatory cyto-
kines through macrophage activation. Transforming growth Dialysis-related amyloidosis (DRA) is a disablingfactor-b (TGF-b) is a multifunctional cytokine that also has
complication in long-term chronic hemodialysis (CHD)chemotactic activity for monocytes at very low (0.1 to 10 pg/mL)
patients [1]. The osteoarticular manifestations of DRAconcentrations and inhibits proinflammatory cytokine produc-
tion of macrophages. In this study, we investigated the role of include carpal tunnel syndrome (CTS), bone cysts, and
TGF-b in the pathogenesis of DRA. destructive spondylarthlopathy [2]. The major constit-
Methods. We performed an immunohistochemical study of uent of amyloid fibril has been identified to be b2-micro-DRA tissues (8 cases) to confirm the existence of TGF-bs and
globulin (b2m) [3]. Recent studies have demonstratedtheir receptors; we also performed a chemotaxis assay of human
that advanced glycation end products (AGE) formedmonocytes as well as enzyme-linked immunosorbent assay
(ELISA) of TGF-b1, tumor necrosis factor-a (TNF-a), inter- by nonenzymatic Maillard reaction between protein and
leukin-1b (IL-1b), and interleukin-1 receptor antagonist sugar are present in b2m-amyloid fibrils of DRA [4, 5].
(IL-1Ra) in the supernatant of human monocyte-derived mac- AGE-modified b2m (AGE-b2m) has also been detectedrophage cell culture under varying conditions of incubation
in the urine and sera of these patients with DRA, butwith TGF-b1, AGE-b2m, and TGF-b1 antibody additions.
not in that of healthy individuals [4]. The pathogenesisResults. There was positive staining for TGF-bs (types 1, 2,
and 3) and their receptors (types I, II, and III) in infiltrated of DRA is initiated by the presence of AGE-induced
macrophages (CD681), synovial lining cell, as well as vascular monocyte chemotaxis and the release of bone-resorbing
walls around amyloid deposition. AGE-b2m also induced TGF-b1 cytokines from macrophages, such as tumor necrosis
production by macrophages in a dose-dependent manner (410 6
factor-a (TNF-a) and interleukin-b (IL-b), which stimu-80 pg/mL at 12.5 mg/mL, 621 6 62 pg/mL at 25 mg/mL, and
late collagenase synthesis in cultured synovial cells [6].776 6 62 pg/mL at 50 mg/mL of AGE-b2m). AGE-b2m induced
The release of these cytokines may subsequently lead tosignificant TNF-a and IL-1Ra production by macrophage. The
addition of exogenous TGF-b1 (0.1 to 10 ng/mL) decreased collagen and connective tissue breakdown.
AGE-b2m–induced TNF-a production and increased IL-1Ra Transforming growth factor-b (TGF-b) is a well-
production in a dose-dependent fashion. IL-1b production was known multifunctional cytokine produced by variety ofnot effected by any experimental conditions. In chemotaxis
cell types: platelets, monocytes, macrophages, lympho-assay, anti–TGF-b1 antibody (0.1 to 10 mg/mL) attenuated
cytes, fibroblasts, osteoblasts, osteoclasts, endothelialAGE-b2m–induced monocyte chemotaxis.
Conclusions. These results provide the first evidence to our cells, and neoplastic cells [7]. TGF-b is involved in the
knowledge for the presence of TGF-b in DRA tissue, as well regulation of cell proliferation, differentiation, angiogen-
as the stimulatory action of AGE-b2m on tissue macrophages. esis, as well as extracellular matrix protein production
[8, 9]. Among its multifunctional effects, TGF-b is also
strongly implicated in the inflammatory process and tis-Key words: amyloidosis, chemotaxis, cytokines, hemodialysis, TGF-b,
AGE-b2m. sue repair from its onset to its resolution [10]. Released
at the site of inflammation, TGF-b promotes leukocyteReceived for publication December 15, 1998
recruitment, including monocytes, neutrophils, and mastand in revised form July 12, 1999
Accepted for publication September 28, 1999 cells, as well as the activation and cytokine synthesis by
these cells [11–16]. For example, TGF-b rapidly inducesÓ 2000 by the International Society of Nephrology
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Table 1. Profile of patients in this study plex (ABC) method using Vectastain ABC kit (Vector
Co., Burlingame, CA, USA). Rabbit antihuman TGF-bsDuration of Cause of renal
Case Age years Sex HD years failure (isoform 1, cat# sc-146; 2, cat# sc-90; 3, cat# sc-82; Santa
Cruz Biotechnology, Santa Cruz, CA, USA), TGF-bR-I1 60.5 F 15.3 CGN
2 48.3 F 14.8 CGN (cat# sc-398), TGF-bR-II (cat# sc-220) polyclonal anti-
3 50.7 M 17.1 CGN bodies, goat antihuman TGF-bR-III (cat# sc-6199) poly-4 56.2 M 20.2 CGN
clonal antibody (Santa Cruz Biotechnology), rabbit anti-5 56.3 M 16.8 CGN
6 65.2 F 16.5 CGN human b2m polyclonal antibody, mouse antihuman
7 49.0 M 16.2 CGN macrophage (CD68) monoclonal antibody (Dako, Car-8 50.1 M 15.4 CGN
pinteria, CA, USA), and mouse antihuman AGEs mono-
Abbreviations are: M, male; F, female; CGN, chronic glomerulonephritis.
clonal antibody (Wako Chemical, Richmond, VA, USA)
were used as the primary antibodies. After inhibition of
the endogenous peroxidase activity, the sections were
incubated with the primary antibodies in a humidifiedincreased levels of steady-state mRNA for TNF-a and
chamber at 48C overnight. The secondary antibody reac-IL-1b, and secretion of TNF-a and IL-1b protein in
tion was accomplished at room temperature by incubat-monocytes [11, 17, 18]. On the other hand, TGF-b also
ing with the biotinylated antibodies for 60 minutes; there-antagonizes the biological activity of IL-1b by the down-
after, the sections were incubated with ABC at roomregulation of IL-1 receptors [19] and synthesis of inter-
temperature for 40 minutes. The immunocomplexes inleukin 1 receptor antagonists (IL-1Ra) [20, 21]. As mono-
the sections were visualized with 0.001% (wt/vol) H2O2cytes differentiate to macrophages, TGF-b has been
and 0.005% diaminobenzidine in Tris-buffered salineshown to suppress macrophage release of reactive oxy-
(pH 7.6), and the sections were then counterstained withgen intermediates [22], reactive nitrogen intermediates
hematoxylin. Negative controls were treated with nonim-[23, 24], and the production of TNF-a and IL-1 [25, 26].
munized IgG as the primary antibody.Thus, TGF-b inhibits the proinflammatory role of differ-
entiated macrophages, thereby promoting termination In vitro preparation of advanced glycation end
of the inflammatory response. product proteins
These well-known properties of TGF-b, along with
Advanced glycation end product proteins were pre-the inflammatory process of DRA, suggest a potential
pared in vitro as previously described [27]. Briefly, 1link between TGF-b and DRA. In an effort to identify
mg/mL of purified normal human b2m (Cortex Biochem,the role of TGF-b in the pathogenesis of DRA, we stud- San Leando, CA, USA) or bovine serum albumin (BSA;
ied the presence of TGF-bs, as well as their receptors Sigma, St. Louis, MO, USA) were incubated at 378C
in the synovial tissues of DRA. In addition, we investi- for 60 days with 100 mmol/L d-glucose in 100 mmol/L
gated the complex interplay between TGF-b, its chemo- phosphate buffer (pH 7.4) containing 200 U/mL of peni-
tactic activity, and activity to modify cytokine release. cillin, 80 mg/mL of gentamicin, and 1.5 mmol/L of phenyl-
Our results indicate the presence of TGF-bs and their methylsulfonyl fluoride under sterile conditions. b2m, in-receptors in the synovial tissues of DRA; in addition, cubated in an identical manner in the absence of glucose,
we demonstrate the ability of AGE-b2m to induce secre- was used as control. Unincubated b2m was also used as
tion of TGF-b from monocyte-derived macrophages, an additional control. After incubation, all samples were
which, in turn, down-regulate proinflammatory cytokine dialyzed against phosphate buffer to remove free glu-
production by these same macrophages. cose. AGE proteins were brownish and were character-
ized by a fluorescence spectrophotometer at a protein
concentration of 0.2 mg/mL in 10 mmol/L phosphateMETHODS
buffer (pH 7.2). The maximum emission fluorescencePathological investigations
intensities at 430 nm were determined upon excitation
Resected specimens of the carpal tunnel synovium at 360 nm [4]. AGE proteins also reacted with anti-AGE
were collected from eight CHD patients. The profile of antibody that recognizes AGE-BSA, AGE-HAS, and
patients is summarized in Table 1 (mean age, 54.5 6 6.1 AGE-hemoglobin, but not nonglycated protein or the
years; range, 48.3 to 65.2; mean duration of hemodialysis, early products of the Maillard reaction. Endotoxin levels
16.5 6 1.7 years; range, 14.8 to 20.2). These were fixed in all samples were measured by LimLus amoebocyte
in formalin, embedded in paraffin, and cut at 4 mm serial lysate assay (E-toxate; Sigma) and were found to be
sections. The existence of the amyloid deposition was below the detection limit (,0.2 ng/mL).
confirmed by Congo red staining in all eight samples.
Chemotaxis assaysAn immunohistochemical study for TGF-bs (isoforms 1,
2, and 3), TGF-b receptors (types I, II, and III), b2m, Human peripheral blood mononuclear cells (PBMCs)
from the blood of four normal healthy volunteers wereAGE, and CD68 was performed by the avidin-biotin com-
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Table 2. TGF-b1 inhibited AGE-b2m-induced TNF-a Statistical analysis
secretion by macrophages
Data are expressed as mean 6 SD. Differences were
TGF-b1 ng/mL
AGE-b2m Ab examined by the unpaired t-test and Mann–Whitney
lg/ml 0 0.1 1 10 10 lg/mL U-test. A P value , 0.05 was considered statistically
0 1366 1366 1064 963 1064 significant.
12.5 372641 306626 196616 148629 428654
25 474660 431647 270634 175620 549652
50 770673 675679 452644 356646 823630 RESULTS
Levels of TNF-a in supernatants from in vitro-derived macrophages cultured
Immunohistochemical detection of TGF-bs andunder various conditions of AGE-b2m (12.5, 25, and 50 mg/mL), TGF-b1 (0.1,
1, and 10 ng/mL) anti–TGF-b1 antibody (10 mg/mL) for 24 hours. TNF-a levels TGF-b receptors in the amyloid tissues
(pg/mL) were determined by ELISA. Data are shown as means 6 sd from four
separate representative experiments using monocytes from different donors (N 5 Immunostaining with anti-AGE antibody demon-
4). Ab is anti–TGF-b1 antibody.
strated that most of AGE was detected in the b2m-posi-
tive amyloid deposited area (Fig. 1 A, B). CD68-positive
macrophages were the major infiltrating cells around the
amyloid deposits and in the synovial lining layer (Fig.isolated by centrifugation on Ficoll-Paque (Pharmacia
1C) in agreement with the previous report [30]. All eightLKB, Uppsala, Sweden) and suspended in Hank’s bal-
samples of DRA tissues demonstrated the presence ofanced salt solution at 4 3 105 cells/mL. Chemotaxis assay
all three human TGF-bs and their receptors. TGF-b1,of human monocyte was performed in 24 wells of double
TGF-b2, and TGF-b3 were mainly detected in the infil-chambers separated by polycarbonate membranes (5 mm;
trated CD68-positive macrophages and synovial liningCorning Coster Corp., Cambridge, MA, USA) [28]. A
cells (Fig. 1 D–F). They were also localized in the vesselPBMC suspension (0.1 mL) was added to the upper
walls and faintly detected in the synovial intimal cells.compartment of the chamber, and the test substances in
Their respective receptors (types I, II, and III) wereHank’s balance salt solution were added to the upper
also localized in the same area as TGF-bs (Fig. 1 G–I).compartment or the lower compartment (0.6 mL), as
Nonimmunized IgG antibody was used as a negativeindicated in Table 2 and Figure 6 (only lower compart-
control (Fig. 1J).ment used). The chambers were incubated at 378C for
four hour. After removing nonmigrating cells, mem-
Cytokine production of humanbranes were fixed in methanol and stained with Giemsa.
monocyte-derived macrophagesEach experiment was performed twice.
Effect of AGE-b2m on TGF-b1 secretion by macro-
Cell culture and measurement of cytokines phages. AGE-b2m induced TGF-b1 production from hu-
man monocyte-derived macrophages in a dose-dependentHuman monocytes were isolated from PBMCs by the
manner (410 6 80 pg/mL at 12.5 mg/mL, 621 6 108adherence method [29]. For this experiment using fully
pg/mL at 25 mg/mL, and 776 6 107 pg/mL at 50 mg/mLdifferentiated human monocyte-derived macrophages,
of AGE-b2m, P , 0.01 vs. normal b2m, as well as com-monocytes were placed in the 24-well culture plates and
allowed to differentiate in RPMI 1640 containing 10% pared with those at concentrations of 12.5 and 50 mg/mL
of AGE-b2m; Fig. 2). Similarly, AGE-BSA (50 mg/mL)fetal bovine serum (Sigma Chemical Co.) for seven days.
All wells were thereafter washed with phosphate-buf- also induced TGF-b1 secretion (832 6 97 pg/mL), sug-
gesting that the AGE moiety is the primary effectorfered saline and incubated overnight in RPMI 1640 with-
out serum. Finally, cells (4 3 105 cells/well) were incu- agent. However, under similar conditions, normal b2m
induced very low levels of TGF-b1 production comparedbated for 24 hours at 378C in various conditions using
several concentrations of b2m, AGE-b2m, recombinant with AGE-b2m (20 6 2 pg/mL at 12.5 mg/mL, 21 6 12
pg/mL at 25 mg/mL, and 28 6 14 pg/mL at 50 mg/mLhuman TGF-b1 (R&D Systems, Minneapolis, MN, USA),
anti–TGF-b1 antibody (cat# AB-101-NA; R&D Sys- of b2m). Anti–TGF-b1 antibody (10 mg/mL) completely
suppressed AGE-b2m–induced TGF-b1 production. LPStems), lipopolysaccharide (LPS; 0128:B12; Sigma) as de-
scribed in the figure legends; supernatants were collected used a positive control (0.1 mg/mL) induced 192 6 24
pg/mL of TGF-b1. Neither anti–TGF-b1 antibody norand assayed for TGF-b1, TNF-a, IL-1b, IL-1Ra, using
enzyme-linked immunosorbent assay (ELISA) kits (R&D medium alone induced a detectable level of TGF-b1
production in the supernatant.Systems, Minneapolis, MN, USA). According to TGF-b1
measurement, the acidification procedure was performed Effect of TGF-b1 on TNF-a secretion by macro-
phages. Table 2 and Figure 3 depict the effect of AGE-following the manufacturer’s instructions. The minimum
detectable level was 7.0 pg/mL for TGF-b1, 4.4 pg/mL b2m on TNF-a production. As can be seen, AGE-b2m
induced significant amounts of TNF-a production in afor TNF-a, 1.0 pg/mL for IL-1b, and 14.0 pg/mL for
IL-1Ra. Each experiment was repeated four times. dose-dependent manner compared with normal b2m-
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Fig. 1. Immunohistochemical study for transforming growth factor be-
tas (TGF-bs) and their receptors in the synovial tissues of dialysis
related amyloidosis (DRA). (A) Anti-AGE immunostaining. (B) Anti-
b2-microglobulin (anti-b2m) immunostaining. (C) Anti-CD68 immuno-
staining. (D) Anti–TGF-b1 immunostaining. (E) Anti–TGF-b2 immuno-
staining. (F) Anti–TGF-b3 immunostaining. (G) Anti–TGF-b receptor
type I immunostaining. (H) Anti–TGF-b receptor type II immunostain-
ing. (I) Anti–TGF-b receptor type III immunostaining. (J) Antinon-
immunized IgG immunostaining. Most of AGE was detected in the amy-
loid deposition. CD68-positive macrophages mainly infiltrated around
the amyloid deposition and in the synovial lining layer. TGF-b1, -2,
and -3 were mainly detected in the infiltrated CD68-positive macro-
phages and synovial lining cells. They were also localized in the vessel
walls, although faintly detected in the synovial intimal cells. Their recep-
tors of types I, II, and III were also almost localized in the same area
of TGF-bs. Original magnifications of (A–J) were 3100.
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Fig. 2. Effect of advanced glycation end-prod-
uct modified b2m (AGE-b2m) on TGF-b1 se-
cretion by macrophages. Levels of TGF-b1 in
supernatants from in vitro-derived macro-
phages cultured under various conditions of
normal b2m (12.5, 25, 50 mg/mL), AGE-b2m
(12.5, 25, and 50 mg/mL), anti–TGF-b1 anti-
body (10 mg/mL), AGE-BSA (50 mg/mL), and
LPS (0.1 mg/mL) for 24 hours. TGF-b1 levels
(pg/mL) were determined by ELISA. Data are
shown as means 6 SD from four separate rep-
resentative experiments using monocytes from
different donors (N 5 4). Abbreviation Ab is
anti–TGF-b1 antibody. *P , 0.01 vs. normal
b2m. **P , 0.01 between 12.5 and 50 mg/mL
of AGE-b2m.
Fig. 3. Effect of TGF-b1 on TNF-a secretion by macrophages. Levels of TNF-a in supernatants from in vitro-derived macrophages cultured
under various conditions of normal b2m (12.5, 25, and 50 mg/mL), AGE-b2m (12.5, 25, and 50 mg/mL), AGE-b2m and TGF-b1 (0.1, 1, and 10
ng/mL), AGE-b2m and anti–TGF-b1 antibody (10 mg/mL), AGE-BSA (50 mg/mL), and LPS (0.1 mg/mL) for 24 hours. TNF-a levels (pg/mL)
were determined by ELISA. Data are shown as means 6 sd from four separate representative experiments using monocytes from different donors
(N 5 4). Ab is anti–TGF-b1 antibody. *P , 0.001 vs. normal b2m. **P , 0.005 between those of 12.5 and 50 mg/mL of AGE-b2m.
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Table 3. TGF-b1 enhanced AGE-b2m-induced IL-1Ra secretion by macrophages
TGF-b1 ng/mL
Ab
AGE-b2m lg/mL 0 0.1 1 10 10 lg/mL
0 69628 431639 788677 1,2406229 90612
12.5 304625 461653 1,1046193 1,6236135 85621
25 4276194 745652 1,5096370 1,8866428 2366104
50 1,9096118 2,2246335 3,1506313 3,3886411 5476199
Levels of IL-1Ra in supernatants from in vitro-derived macrophages cultured under various conditions of AGE-b2m (12.5, 25, and 50 mg/mL), TGF-b1 (0.1, 1,
and 10 ng/mL), and anti–TGF-b1 antibody (10 mg/mL) for 24 hours. IL-1Ra levels (pg/mL) were determined by ELISA. Data are shown as means 6 SD from four
separate representative experiments using monocytes from different donors (N 5 4). Ab is anti–TGF-b1 antibody.
induced TNF-a production (372 6 41 pg/mL in response report [32]. Neither anti–TGF-b1 antibody nor medium
alone stimulated IL-1Ra secretion. TGF-b1 alone stimu-to 12.5 mg/mL of AGE-b2m vs. 41 6 9 pg/mL in response
to 12.5 mg/mL of b2m; 474 6 60 pg/mL in response to 25 lated IL-1Ra secretion as previously reported (Table 3)
[20, 21].mg/mL of AGE-b2m vs. 45 6 17 pg/mL in response to 25
mg/mL of b2m; 770 6 73 pg/mL in response to 50 mg/mL Effect of TGF-b1 on IL-1b secretion by macrophages.
A low level (less than 4 pg/mL) of IL-1b was secretedof AGE-b2m vs. 91 6 37 pg/mL in response to 50 mg/mL
of b2m, P , 0.001 all three different concentrations) [6]. into the culture media by culture-derived macrophages
under all conditions, including LPS (Fig. 5). There wasAGE-BSA (50 mg/mL) also induced TNF-a production
(690 6 110 pg/mL) as previously reported [31]. no effect of TGF-b1 on IL-1b secretion.
The addition of exogenous TGF-b1 (0.1 to 10 ng/mL)
Involvement of TGF-b in AGE-b2m–induceddecreased AGE-b2m–induced TNF-a production in a
monocyte chemotaxisdose-dependent manner (Table 2 and Fig. 3). On the other
hand, the combination of AGE-b2m and anti–TGF-b1 To determine the chemotactic activity of TGF-b1 for
monocytes at different concentrations [11], recombinantantibody (10 mg/mL) slightly but not significantly in-
creased TNF-a production compared with AGE-b2m human TGF-b1 was tested at concentrations ranging
from 0.1 to 10 ng/mL (Fig. 6A). Compared with N-alone. Similar results were observed with AGE-BSA–
induced TNF-a production (data not shown). LPS used Formyl-Met-Leu-Phe(FMLP) (1026 m) as a positive con-
trol, TGF-b1 had a lower chemotactic activity that wasas a positive control (0.1 mg/mL) induced 1798 6 324
pg/mL of TNF-a production. Anti–TGF-b1 antibody and present even at a concentration as high as 10 ng/mL, and
was not concentration dependent. Checkerboard analy-medium alone induced a very low level of TNF-a produc-
tion in the supernatant (10 6 4 and 13 6 6 pg/mL, sis indicated that cell migration was not random (chemo-
kinetic) but directional (chemotactic; Table 4). The pres-respectively). TGF-b1 alone did not stimulate TNF-a
production (Table 2). ence of b2m did not appear to affect the chemotactic
activity of TGF-b1 at either of the three different concen-Effect of TGF-b1 on IL-1Ra secretion by macrophages.
As shown in Table 3 and Figure 4, AGE-b2m also in- trations. b2m alone did not enhance the chemotactic ac-
tivity and was no different than medium alone (Fig. 6A).duced significant amounts of IL-1Ra from human mono-
cyte-derived macrophages in a dose-dependent manner Next, the interaction between TGF-b and AGE-b2m
in determining monocyte chemotaxis was tested. Asin the culture media compared with that induced by
normal b2m (304 6 25 pg/mL in response to 12.5 mg/mL shown in Figure 6B, AGE-b2m induced monocyte che-
motaxis in a dose-dependent manner. Twenty-five mg/mLof AGE-b2m vs. 69 6 22 pg/mL in response to 12.5
mg/mL of b2m, P , 0.05) Similar differences were ob- of AGE-b2m induced comparable chemotactic activity
to TGF-b1. The addition of TGF-b1 (0.1 to 10 ng/mL)served in response to 50 mg/mL of AGE-b2m and b2m
(P , 0.01). Furthermore, like AGE-b2m, AGE-BSA (50 did not significantly change the chemotactic activity of
AGE-b2m alone. AGE-BSA (50 mg/mL) also showedmg/mL) also induced IL-1Ra production (2160 6 254
pg/mL). The addition of exogenous TGF-b1 (0.1 to equivalent chemotactic activity to that of AGE-b2m.
On the other hand, the addition of anti–TGF-b1 anti-10 ng/mL) enhanced AGE-b2m–induced IL-1Ra produc-
tion in a dose-dependent manner. In contrast, anti– body at concentrations of greater than 0.1 mg/mL slightly
inhibited AGE-b2m–induced monocytes chemotaxis. ForTGF-b1 antibody (10 mg/mL) inhibited but did not com-
pletely suppress AGE-b2m–induced IL-1Ra production. example, at a concentration of 10 mg/mL of anti–TGF-b1
antibody, AGE-b2m–induced chemotaxis at a concentra-Similar results were observed with AGE-BSA–induced
IL-1Ra production (data not shown). LPS (0.1 mg/mL) tion of 12.5 mg/mL was reduced by 55%, whereas at a
concentration of 50 mg/mL, AGE-b2m chemotaxis wasdid not stimulate IL-1Ra secretion from culture-derived
macrophage, and this result is consistent with a previous reduced by 50%. There was no difference between the
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Fig. 4. Effect of TGF-b1 on IL-1Ra secretion by macrophages. Levels of IL-1Ra in supernatants from in vitro-derived macrophages cultured
under various conditions of normal b2m (12.5, 25, and 50 mg/mL), AGE-b2m (12.5, 25, and 50 mg/mL), AGE-b2m and TGF-b1 (0.1, 1, and 10
ng/mL), AGE-b2m and anti–TGF-b1 antibody (10 mg/mL), AGE-BSA (50 mg/mL), and LPS (0.1 mg/mL) for 24 hours. IL-1Ra levels (pg/mL)
were determined by ELISA. Data are shown as means 6 SD from four separate representative experiments using monocytes from different donors
(N 5 4). Ab is anti–TGF-b1 antibody. *P , 0.05 vs. 12.5 mg/mL normal b2m. **P , 0.01 vs. 50 mg/mL normal b2m. ***P , 0.005 between those
of 12.5 and 50 mg/mL of AGE-b2m.
extent of inhibition by anti–TGF-b1 antibody at concen- matory process [10]. By using human culture-derived
trations of 0.5 versus 10 mg/mL. IgG did not have an affect macrophages, our study demonstrated the possible in-
on AGE-b2m–induced monocyte chemotaxis (Fig. 6C). volvement of TGF-b in cytokine traffic related to the
formation of DRA. Thus, although AGE-b2m is a well-
known proinflammatory mediator demonstrated by itsDISCUSSION
ability to induce large concentrations of TNF-a, it also
The results of this study have several important impli- induces large amounts of TGF-b1 production from hu-
cations on the pathogenesis of DRA. Specifically, to our man monocyte-derived macrophages in a dose-depen-
knowledge, this is the first study to demonstrate that all dent fashion (Fig. 2). Our study also demonstrated that
three human isoforms of TGF-bs and their receptors
TGF-b1 decreases AGE-b2m–induced TNF-a produc-are localized in the infiltrated macrophages and synovial
tion, as shown in Figure 3. This is consistent with the well-lining cells around AGE-modified amyloid deposits in
known bifunctional actions of TGF-b, which displayssynovial tissues of DRA. The pathobiology of DRA is
inhibitory as well as stimulatory effects of cytokine re-initiated by AGE-b2m formation on AGE-modified col-
lease in diverse cells. Specifically, TGF-b has been re-lagen [33]. This study immunohistochemically indicated
ported to stimulate human mononuclear leukocytes tothat AGE formation is implicated in the production of
accumulate mRNA for TNF and IL-1 [11, 12, 17, 18], asTGF-bs and their receptors in DRA tissues. Once se-
well as to secrete TNF and IL-1 protein [18]. On the othercreted into the extracellular environment, TGF-b inter-
hand, in inflammatory peritoneal murine macrophages,acts with specific membrane receptors in which receptor
TGF-b neither elicited TNF nor IL-1 protein productiontype I and type II forming a heteromeric complex are
nor induced their respective cytokine mRNA [26]. Simi-required for signal transduction [34]. Thus, we speculate
larly, when human PBMCs or murine macrophages werethat this interaction mechanism may occur in DRA tissues.
stimulated with LPS, the release of TNF and IL-1 wasTransforming growth factor-b is a well-known multi-
functional cytokine that is often implicated in the inflam- inhibited by TGF-b [17, 25]. In this study, TGF-b elicited
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Fig. 5. Effect of TGF-b1 on IL-1b secretion by macrophages. Levels of IL-1b in supernatants from in vitro-derived macrophages cultured under
various conditions of normal b2m (12.5, 25, and 50 mg/mL), AGE-b2m (12.5, 25, and 50 mg/mL), AGE-b2m and TGF-b1 (0.1, 1, and 10ng/mL),
AGE-b2m and anti–TGF-b1 antibody (10 mg/mL), AGE-BSA (50 mg/mL), and LPS (0.1 mg/mL) for 24 hours. IL-1b levels (pg/mL) were determined
by ELISA. Data are shown as means 6 sd from four separate representative experiments using monocytes from different donors (N 5 4). Ab is
anti–TGF-b1 antibody.
an inhibitory effect on AGE-induced TNF-a production TGF-b1 may be indirectly involved in IL-1b activity. A
significant finding in our study is that AGE proteinsby monocyte-derived macrophages.
Unlike previous reports of IL-1b secretion by AGE- induced IL-1Ra production from monocyte-derived
macrophages (Fig. 4). The robust inhibition of IL-1Rab2m [6, 28], our study indicates that AGE-proteins do
not stimulate IL-1b secretion from human monocyte- production by the addition of anti–TGF-b1 antibody
strongly suggests the involvement of TGF-b in this pro-derived macrophages. Furthermore, TGF-b had no stim-
ulatory effect on IL-1b secretion by these macrophages cess, most likely secondary to its anti-inflammatory ef-
fect. Our in vitro model therefore suggests that, although(Fig. 5). A possible explanation for this result is that
human monocytes cultured over six days exhibited low AGE proteins promote a proinflammatory action via its
promotion of TNF-a release, they also have an anti-levels of both IL-1b mRNA and protein production in
comparison with freshly isolated monocytes under all inflammatory action via its promotion of TGF-b release.
Nevertheless, it is likely that the net effect is a proin-experimented conditions, including LPS stimulation [35].
Our results are thus consistent with recent studies that flammatory action, resulting in the presence of chronic
inflammation in DRA.have suggested that various populations of human tissue
macrophages, including alveolar and peritoneal cells, are In this study, we have also demonstrated that AGE
proteins may induce the accumulation of monocytes viapoor agonists for IL-1b production in response to LPS
stimulation [35–37]. In addition, the previous reports its production of TGF-b. TGF-b is a well-known potent
chemotactic factor for monocytes at concentrations rang-have shown that TGF-b antagonizes the biologic activity
of IL-1b in two ways: down-regulation of IL-1 receptors ing from 0.1 to 10 pg/mL [11]. In our study, even at a high
concentration of TGF-b1 (0.1 to 10 ng/mL), TGF-b1 stillbecause of a direct effect of TGF-b [19] and induction
of IL-1Ra, which competitively binds to the IL-1 receptor had chemotactic activity (Fig. 6A), although it was weaker
compared with the previous report [11]. AGE-b2m alsowithout triggering an activation signal [20, 21].
Although we were not able to show any direct effect had a direct chemotactic activity at a low concentration
(12.5 mg/mL), which increased further at high concen-of TGF-b1 on IL-1b secretion, our results suggest that
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Fig. 6. Involvement of TGF-b1 in AGE-b2m
induced monocyte chemotaxis. Monocyte mi-
gration was tested in response to increased
concentrations of (A) TGF-b1 (0.1, 1, and 10
ng/mL), normal b2m (12.5, 25, and 50 mg/mL)
alone and those various combinations (B)
AGE-b2m (12.5, 25, and 50 mg/mL), TGF-b1
(0.1, 1, and 10 ng/mL) alone and those various
combinations, AGE-BSA (50 mg/mL; (C) vari-
ous combinations of AGE-b2m (12.5, 25, and
50 mg/mL) and anti–TGF-b1 antibody (Ab;
0.1, 0.5, 1, and 10 mg/mL), and nonimmune
IgG. FMLP (1026 mol/L) and medium itself
were used as a positive, negative control, re-
spectively. Chemotactic activity is defined as
the mean number of monocytes that had mi-
grated to the lower surface of the filters. The
number of cells per eight high-power fields
(hpf; 3400) was counted through a micro-
scope. Cell migration assay was duplicated us-
ing healthy human PBMCs. TGF-b1 had the
same level of chemotactic activity during this
range. Data are shown as means 6 SD from
four representative experiments (N 5 4).
trations (25, 50 mg/mL). Although the combination of that TGF-b1 is involved in AGE-b2m–induced monocyte
chemotaxis to certain extent, but there are other factors,TGF-b and AGE-b2m did not increase chemotactic activ-
ity, the addition of anti-TGF-b1 antibody suppressed it yet to be identified, that play a role in this process.
A recent report suggested that the interaction of AGEby approximately 50% (Fig. 6C). This result suggests
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Table 4. Checkerboard analysis of human monocytes migration REFERENCES
response to TGF-b1
1. Drueke TB: Beta-2-microglobulin amyloidosis and renal bone dis-
TGF-b1 ng/ml in upper compartment ease. Miner Electrolyte Metab 17:261–272, 1991TGF-b1 ng/ml in
2. Koch KM: Dialysis-related amyloidosis [clinical conference]. Kid-lower compartment 0 0.1 1 10
ney Int 41:1416–1429, 1992
0 6.263.4 8.463.7 8.663.2 6.962.8 3. Gejyo F, Yamada T, Odani S, Nakagawa Y, Arakawa M, Kuni-
0.1 21.363.4 9.364.1 8.363.4 7.163.2 tomo T, Kataoka H, Suzuki M, Hirasawa Y, Shirahama T, Cohen
1 20.762.1 19.964.2 7.563.9 6.864.0 AS, Schmid K: A new form of amyloid protein associated with
10 20.962.9 21.163.8 19.763.6 6.764.3 chronic hemodialysis was identified as beta 2-microglobulin. Bio-
chem Biophys Res Commun 129:701–706, 1985Data are shown as means 6 sd from four representative experiments and
4. Miyata T, Oda O, Inagi R, Iida Y, Araki N, Yamada N, Horiuchichemotactic activity is defined as mean number of monocytes that had migrated
to lower surface of the filters in response to the TGF-b1 (0.1, 1, and 10 ng/mL). S, Taniguchi N, Maeda K, Kinoshita T: Beta 2-microglobulin
The number of cells per eight high-power fields (3400) was counted through a modified with advanced glycation end products is a major compo-
microscope. Cell migration assay was duplicated using healthy human PBMC. nent of hemodialysis-associated amyloidosis. J Clin Invest 92:1243–
1252, 1993
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of advanced glycation end products in dialysis-related amyloidosis.and the receptor for AGE (RAGE) on monocyte con- Kidney Int 48:771–778, 1995
tributed to monocyte chemotaxis and was prevented by 6. Miyata T, Inagi R, Iida Y, Sato M, Yamada N, Oda O, Maeda
K, Seo H: Involvement of beta 2-microglobulin modified with ad-soluble RAGE or anti-RAGE antibody [38]. Although
vanced glycation end products in the pathogenesis of hemodialysis-this study showed that AGE proteins induced monocyte associated amyloidosis: Induction of human monocyte chemotaxis
chemotaxis through TGF-b, it is unclear how TGF-b and and macrophage secretion of tumor necrosis factor-alpha and
interleukin-1. J Clin Invest 93:521–528, 1994RAGE interact with each other. Further investigations
7. Roberts AB, Thompson NL, Heine U, Flanders C, Sporn MB:are necessary to clarify this complex interaction. Transforming growth factor-beta: Possible roles in carcinogenesis.
The exact mechanism by which TGF-b may be in- Br J Cancer 57:594–600, 1988
8. Massague J: The transforming growth factor-beta family. Annuvolved in DRA of dialysis patients is not clear at this
Rev Cell Biol 6:597–641, 1990time. Several studies have shown that the circulating
9. Roberts AB, Sporn MB: Physiological actions and clinical applica-
TGF-b level is significantly higher in hemodialysis pa- tions of transforming growth factor-beta (TGF-beta). Growth Fac-
tors 8:1–9, 1993tients compared with normal subjects [39–41]. In the
10. Wahl SM, McCartney-Francis N, Mergenhagen SE: Inflamma-circulation, TGF-b essentially exists in an inactive com-
tory and immunomodulatory roles of TGF-beta. Immunol Today
plex with the protease inhibitor a2-macroglobulin (a2M). 10:258–261, 1989
11. Wahl SM, Hunt DA, Wakefield LM, McCartney-Francis N,Consequently, TGF-b may exist in two distinct, biologi-
Wahl LM, Roberts AB, Sporn MB: Transforming growth factorcally inactive forms: the original latent complex with its
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